Saccharo

Saccharo is a private, preclinical-stage biotech leveraging a novel, serendipitously discovered immune evasion pathway centered on the polysaccharide dPSA. The company's core hypothesis is that dPSA, re-expressed on cancer cells and associated with surface nucleolin, represents a highly specific and conserved target that could overcome limitations of protein-targeted therapies, such as off-target toxicity and resistance. Its pipeline, led by the ADC candidate SAC-253, is being advanced through a recent collaboration with Memorial Sloan Kettering, supported by a leadership team with deep industry experience from top biopharma firms. Saccharo's approach aims to create therapies with a broad potential application across solid and hematologic cancers.

Platform targeting the de-N-acetyl-polysialic acid (dPSA) immune shielding pathway. dPSA is a cancer-specific polysaccharide linked to cell surface nucleolin, exploited by tumors to evade immune detection. The platform generates high-affinity antibodies against dPSA for development into various therapeutic formats.

Saccharo competes in the crowded oncology space but claims a unique niche by targeting a polysaccharide (dPSA) rather than a protein. Its primary competitors are developers of ADCs and targeted therapies against established targets like HER2, Trop2, and others. Its key differentiator is the potential for superior cancer specificity and a lower risk of resistance, but it must prove this clinically against well-funded incumbents and novel modalities like cell therapies.